Aerovance is a technology company.
Aerovance has raised $130.0M across 3 funding rounds.
Aerovance has raised $130.0M in total across 3 funding rounds.
Aerovance is a biopharmaceutical company developing biologics and clinical-stage therapies for respiratory, allergic, and inflammatory diseases, such as asthma and atopic dermatitis.[1][3][4] Its pipeline includes drugs like Pitrakinra, an IL-13R and IL-4Rα inhibitor that reached pending or discontinued phases for indications like dermatitis.[3] Originally focused on respiratory biologics since 2004, conflicting sources note a technology platform for converting injectable drugs to oral forms, though primary emphasis remains on disease-specific treatments.[2][4] The company serves patients with unmet needs in these areas, advancing four drugs into mid-stage development from Berkeley, California (with some mentions of Worcester, Massachusetts).[2][4][5]
Founded in 2004, Aerovance emerged as a start-up biotech firm with researchers targeting biologics for inflammatory and respiratory diseases.[4] Key early focus included advancing multiple drug candidates into clinical stages, with Pitrakinra entering trials as early as November 2007 and March 2009 for atopic dermatitis and related conditions.[3] Headquartered in Berkeley, United States, the company built traction through a mid-stage pipeline, though specific founders are not detailed in available records.[5][6] Pivotal moments involved progressing four therapies, positioning it as an innovator in biologics despite later pipeline discontinuations.[3][4]
Aerovance rides the trend of biologics innovation in respiratory and immunology markets, where inflammatory diseases affect millions and demand targeted therapies amid rising allergies and asthma prevalence.[1][4] Timing aligns with early 2000s biotech boom in protein-based drugs, influencing the ecosystem by contributing to IL-4/IL-13 inhibitor research that paved the way for approved treatments like dupilumab.[3] Market forces favoring it include unmet needs in oral alternatives to injectables and a shift toward patient-centric delivery, though pipeline setbacks highlight biotech risks like trial discontinuations.[2][3]
Aerovance's legacy in respiratory biologics underscores early promise in immunology, but discontinued pipeline elements like Pitrakinra suggest acquisition or pivot potential rather than standalone growth.[3] Next steps could involve licensing tech for oral conversions amid trends in drug reformulation and AI-driven biotech revival.[2] Its influence may evolve through foundational contributions to allergy treatments, tying back to its role as a 2000s pioneer advancing clinical-stage hope for respiratory patients.[1][4]
Aerovance has raised $130.0M in total across 3 funding rounds.
Aerovance's investors include Nest.Bio Labs.
Aerovance has raised $130.0M across 3 funding rounds. Most recently, it raised $38.0M Venture Round in April 2009.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Apr 1, 2009 | $38.0M Venture Round | Nest.Bio Labs | |
| Mar 1, 2007 | $60.0M Series C | Nest.Bio Labs | |
| Aug 1, 2004 | $32.0M Series B | Nest.Bio Labs |